Stockscreener 앱 받기
28.33
2.68%
0.74
시간 외 거래:
28.33
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Why (BEAM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Analyst bullish on Beam Therapeutics (BEAM) over drug program trajectory - MSN
Beam Therapeutics (NASDAQ:BEAM) Upgraded at Canaccord Genuity Group - MarketBeat
Canaccord Genuity Initiates Coverage of Beam Therapeutics (BEAM) with Buy Recommendation - Nasdaq
Canaccord Genuity initiates Beam Therapeutics stock with buy rating - Investing.com UK
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Why Beam Therapeutics Inc. stock appeals to analystsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - mfd.ru
Canaccord Genuity Initiates Coverage on BEAM with a 'Buy' Rating - GuruFocus
Canaccord Genuity initiates Beam Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - TradingView
Growth Recap: Can Beam Therapeutics Inc sustain its profitabilityWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Aug EndMonth: Should I trade or invest in MAG Silver CorpJuly 2025 Reactions & Entry and Exit Point Strategies - baoquankhu1.vn
Ideas Watch: Is Cosmos Health Inc in a consolidation phase2025 Major Catalysts & Accurate Trade Setup Notifications - baoquankhu1.vn
13 Hot Stocks to Buy with the Highest Upside Potential - Insider Monkey
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory - Finviz
Readystate Asset Management LP Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (BEAM) to Release Earnings on Tuesday - MarketBeat
Analyst Calls: Is ICCC backed by strong institutional buyingM&A Rumor & Breakout Confirmation Trade Signals - baoquankhu1.vn
Here is Why Beam Therapeutics (BEAM) Appears so Attractive - Insider Monkey
Assessing Beam Therapeutics (BEAM) Valuation After FDA Expedited Pathway And New Gene‑Editing Patent License - Yahoo Finance
17 Biotechnology Stocks with More Than 50% Upside - Insider Monkey
Why Beam Therapeutics (BEAM) Is Up 5.3% After New Gene-Editing IP Deal And FDA Fast Track - Yahoo Finance
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval - Insider Monkey
13 Best Innovative Stocks to Buy According to Wall Street Analysts - Insider Monkey
Beam Therapeutics Secures Standby License for Key Patents - The Globe and Mail
Wedbush Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
Prime Editing and CRISPR Market Set for Explosive Growth at 24.1% - openPR.com
Trading Recap: Can Beam Therapeutics Inc sustain its profitabilitySell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
Best CRISPR Companies to Buy in 2026 and How to Invest in Them - The Motley Fool
Buyout Rumor: Will Alector Inc stock hit new highs in YEAR2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Volume Summary: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (BEAM) - Stock Traders Daily
Aug Reactions: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Fed Impact & Verified Technical Trade Signals - baoquankhu1.vn
FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus
What’s the outlook for Beam Therapeutics Inc.’s sectorJuly 2025 Levels & Fast Gain Swing Trade Alerts - mfd.ru
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Biotech Innovator with 73% Potential Upside - DirectorsTalk Interviews
Beam Therapeutics Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics announces upcoming board member resignation - TipRanks
Director Carole Ho to leave Beam Therapeutics (NASDAQ: BEAM) board - Stock Titan
Bear Alert: Can Beam Therapeutics Inc. sustain its profitability2025 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Beam Therapeutics Inc. (BEAM) Stock Analysis: A 69% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Beam Therapeutics: A Critical Year for Clinical Validation - AD HOC NEWS
Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Avoiding Lag: Real-Time Signals in (BEAM) Movement - Stock Traders Daily
Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM - MarketBeat
Wall Street Zen Upgrades Beam Therapeutics (NASDAQ:BEAM) to Hold - MarketBeat
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) - Finviz
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ARK Investment Acquires 116K Shares of Beam Therapeutics (BEAM) - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Look at the 46.90% Potential Upside and Cutting-Edge Genetic Medicine Advancements - DirectorsTalk Interviews
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
2.25%
0.47%
자본화:
|
볼륨(24시간):